

Received: 15 march 2020

Revision received: 16 march 2020

Accepted: 17 march 2020

eISSN: 2717-5138

www.rriemd.com

DOI:10.33702/rremd.2020.2.1.03; 2020, 2 (1) 18-22

Case Report

Daily improvement of glucose variability by Continuous Glucose Monitoring (CGM)

Hiroshi Bando^{1,2,3}, Yoshikane Kato³, Setsuko Kanazawa³, Mayumi Tanaka³, Etsuko Sueki³, Hiroe Kanagawa³, Takafumi Kawata³, Atsuko Kawahito³, Aya Aihara³

¹Medical Research / Tokushima University, Tokushima, Japan

²Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Kyoto, Japan

³Kanaiso Hospital, Tokushima, Japan

ABSTRACT

Continuous Glucose Monitoring (CGM) has been recently applied in the clinical diabetic practice. Authors have continued research of glucose variability. In this study, 51 year-old female patient with Type 1 diabetes mellitus (T1DM) was investigated. She has given multiple daily insulin injection (MDI) for long and her recent daily glucose profile was unstable. After applied with FreeStyle Libre, her blood variability was improved with the average glucose from 222 mg/dL to 135 mg/dL, which was partly from her motivation for better diabetic control. Thus, CGM may become a trigger to give beneficial influence for regular lifestyle of the patients.

Key words: Continuous Glucose Monitoring (CGM) FreeStyle Libre, multiple daily insulin injection (MDI), Type 1 diabetes mellitus (T1DM), Japan LCD promotion association (JLCDPA)

Abbreviation: CGM: Continuous Glucose Monitoring, T1DM: type 1 diabetes mellitus MDI: multiple daily insulin injection, LCD: Low Carbohydrate Diet, CR: Calorie Restriction

Citation: Hiroshi BANDO. (2020). Daily improvement of glucose variability by Continuous Glucose Monitoring (CGM), Recent Research in Endocrinology and Metabolic Disorder, 2(1), 18-22. <http://dx.doi.org/10.33702/rremd.2020.2.1.03>

Author for correspondence: Hiroshi BANDO, Tokushima University, Tokushima, Japan

Email: pianomed@bronze.ocn.ne.jp

Copyright: Hiroshi BANDO

License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). <http://creativecommons.org/licenses/by/4.0>

INTRODUCTION

Diabetes mellitus has been important disease across the world. It has been treated by adequate glycemic control, for which some diabetic standard guidelines were presented [1]. As to diabetic therapy, nutritional treatment has been the basic method and other various dietary therapies have been reported [2]. They include calorie restriction (CR) (low-fat), vegetarian, Mediterranean, moderate carbohydrate, low-carbohydrate diet (LCD), high-protein, control, low glycemic index/ glycemic load (GI/GL) and Paleolithic [2]. Among them, recent topics would be mainly LCD, CR, and Mediterranean diet and so on.

It has been almost classified into 2 types, which are Type 2 diabetes mellitus (T2DM) and Type 1 Diabetes Mellitus (T1DM). As for T2DM, recent topics include some kinds of anti-diabetic oral agents such as SGLT2 inhibitors [3-5] and nutritional treatment such as LCD [6-7]. LCD was initiated and became popular broadly in medical and health region [6-7]. LCD has been reported to show more beneficial effect than CR [8].

Concerning LCD, authors and colleagues have firstly reported LCD in Japan [9]. Furthermore, we have continued clinical practice and education concerning LCD, in which super LCD, standard LCD and petite LCD have been proposed for continuation of LCD in daily life [10]. We have reported various research about LCD, CR, M value, meal tolerance test (MMT), CGM, and others for long [11,12]. From medical social point of view, we have developing social movement of LCD through of Japan LCD promotion association (JLCDPA) [11,12].

As for T1DM, recent topics include evaluation methods such as new treatment method such as ultra-long acting insulin plus ultra-rapid insulin [13], and continuous glucose monitoring (CGM) [14]. Among them, CGM has been developed for some years, there several reports showing clinical effect of detecting hypoglycemia episodes [15]. Furthermore, beneficial CGM reveals higher self-efficacy, lower diabetes distress, simultaneous response and other positive technology points [16,17]. GM has been rather popular recently in the clinical practice [17]. It has been a sensor-based apparatus for diabetes mellitus [18]. Most well-known device has been FreeStyle Libre, that is from Abbott Diabetes Care Inc., CA, United States [18]. It has been evaluated to be reliable for long, because it is simple and useful for detecting detail fluctuation of blood variability. Furthermore, it is convenient with small size and precise data [19].

Among our various diabetic practice and research, we have reported diabetic cases so far. In this article, we describe a case with T1DM received CGM and showed the improvement of glucose variability in short period.

CASE REPORT

Present History: The case was 51-year-old female patient with T1DM with about 8 years of duration. She has continued to have insulin therapy for years. The control of diabetic state has been almost fair with HbA1c 7.2-8.4% until half years ago. After that, however, her diabetic control became unstable, with the range of 61 mg/dL to 400 mg/dL. At that time, HbA1c value was increased to 9.0% 2 months ago. Consequently, diabetes staffs in charge recommended her to check the profile of blood glucose using FreeStyle Libre.

Physical examination: She showed unremarkable physical status, and no consciousness disorder from hyper or hypoglycemia. The vital signs were normal, and no specific diabetic neurological disorders were found. She has normal range of body mass index (BMI) around 21.0 kg/m².

Laboratory test: The data of the laboratory tests were as follows: The standard biochemical data were: AST 18 U/mL, ALT 21 U/mL, r-GT 23 U/mL, BUN 19 mg/dL, Cre 0.6 mg/dL, Uric Acid 5.7 mg/dL, HDL 36 mg/dL, LDL 98 mg/dL, postprandial TG 369 mg/dL, WBC 5900 / μ L, RBC 4.39 x 10⁶/ μ L, Hb 13.3 g/dL, Plt 27.5 x 10⁴/ μ L. Data related diabetes were HbA1c 9.5%, pre-prandial glucose 146 mg/dL.

Insulin treatment: She has been treated for long as multiple daily insulin injection (MDI), with four times of insulin per day. She was provided 2 kinds of insulin. They are Novo rapid (Novo Nordisk) given three times per day just before three meals. Further, she was given insulin Glargine (Eli Lilly and Company) once a day at night at 2100h – 2300h. Their brand names were Insulin Aspart by pre-filled pen including 100 units/mL, and Insulin Glargine by BS injection kit FFP including 300 units/mL. Recent dose of insulin was 25, 23, 20 units of Aspart, and 16 units of Glargine.

METHODS

The glucose variability of the case was investigated by FreeStyle Libre (Abbott, USA) [18]. Blood glucose profile was studied for 14 days. The medical apparatus FreeStyle Libre (Abbott, USA) has showed the reliability for the stable glucose data [19]. It showed stable and beneficial results such as trend accuracy, point accuracy, alarms, calibration, and the stability of the sensor, time lag and traceability [20]. It also showed the stable results along the guideline of Clinical and Laboratory Standards Institute (CLSI) [14].

RESULTS

Using the CGM apparatus FreeStyle Libre, blood glucose profiles are shown on day 3, 6, 9 and 12 (Figure 1). The average value of blood glucose analyzed by FreeStyle Libre showed 222 mg/dL, 148 mg/dL, 140 mg/dL and 135 mg/dL, respectively. Regarding the pattern of glucose profile, each data showed different in these days. One of the common characteristic results would be the elevated tendency during 1130h – 1430h. During midnight, glucose pattern was not the same. There is an estimated HbA1c value calculated by FreeStyle Libre, which was 7.3% or 56 mmol/mol. In contrast, actual HbA1c value in the out clinic showed 7.9% or 60 mmol/mol. Both data has a discrepancy between them.

DISCUSSION

Concerning CGM, the advantage would be obtaining the instant and correct glucose value. It can bring the improvement of variability of glucose, less episode of hypoglycemia, and better cost-effectiveness [21,22].

There are recently some guidelines for CGM application from the endocrine society [23]. For the results of summarized of RCTs, CGM could reduce the HbA1c value by 0.28%, and lessen the episode of hypoglycemia [23]. Furthermore, CGM will have the possibility of implantable variability for coming generation in the future [24,25].




Figure 1: Blood glucose level - (Graf:-1Day -3 Estimated HbA1c is 7.3% or 56 mmol/mol By FreeStyle Libre.); (Graf:-2, Day 6:- Measured HbA1c is 7.9% or 60 mmol/mol from out clinic data.); (Graf:-3 Day 9:- Glucose profile became in the range of 80-180 mg/dL all day long); (Graf:-4 Day 12: FreeStyle Libre)

Along with the CGM development, adults and children with T1DM will reduce instable variability and improve glycemic control [26,27]. When T1DM case wear CGM and regulate blood glucose level adequately, the case has simultaneously large benefit of real time CGM (rtCGM) [26,28]. Consequently, diabetic therapy with rtCGM can expect ideal profile of glucose in the case of MDI [29,30]. CGM can also give more effective management of glycemic rate of change (ROC) in order to adjust the dose of insulin [31].

In this study, there was a difference of HbA1c value in 7.9% and 7.4% between out clinic and analyzed data by FreeStyle Libre. There have been similar reports found so far [32]. One reason would be that CGM cannot detect occasional abrupt increases in blood glucose [32]. In fact, blood glucose levels are measured every 7.5 min to 15 min in FreeStyle Libre and FreeStyle Libre Pro [33]. This problem will be further investigated from various points of view.

According to the previous report, FreeStyle Libre showed safety, accuracy and acceptability for pediatric patients with T1DM [19]. In contrast, mean difference (SD) of FreeStyle Libre was -43.4 (SD 20) mg/dL, which was rather large [34]. Moreover, as the value was in lower range, the glucose rise after meal was underestimated [32]. The glucose value of mean absolute relative difference (MARD) was 20.3%, 14.7%, 9.6%, respectively for the three ranges of glucose (<72, 72-180, 181<) [33].

In this study, the case with T1DM showed unstable glucose variability some months ago. At that time, it was suggested that she had irregular lifestyle [17]. After that, her daily schedule would become rather improved with less unstableness. It seems to be beneficial for her to check real time blood glucose, when wearing FreeStuye Libre for 2 weeks [35]. According to the guideline of CGM in 2019, there are recommendations for reduction of hypoglycemia, which revealed the evidence level as rank A [1].

The reason of her unstable lifestyle was evaluated with patients herself and medical staffs. She has worked as part time job with rather unstable working shift. When she was in bad diabetic control, her daily schedule was influenced to much extent. After that, she has decided her mind to keep regular hours, especially wake up, meals and sleep time. Consequently, her regular life has been kept with the trigger of CGM in FreeStyle Libre.

In summary, CGM was applied to the patient with T1DM, and detail glucose variability was investigated. Using FreeStyle Libre, her average glucose was reduced from 222 mg/dL to 135 mg/dL with her motivation for better diabetic control. Thus, CGM may become a trigger to give beneficial influence for regular lifestyle of the patients. Current report would be expected to be some reference for clinical practice.

Acknowledgment: Authors would like to express our gratitude for understanding and cooperation to the patient and related staffs concerning this study.

Conflicts of interest: The authors declare no conflict of interest.

REFERENCES

- [1] American Diabetes Association (2019) 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes 2019. *Diabetes Care* 42(Suppl.1):S90–S102
- [2] Schwingshackl L, Chaimani A, Hoffmann G, Schwedhelm C, Boeing H (2017) Impact of different dietary approaches on glycemic control and cardiovascular risk factors in patients with type 2 diabetes: a protocol for a systematic review and network meta-analysis. *Syst Rev*. 6(1):57. doi: 10.1186/s13643-017-0455-1.
- [3] EMPA-REG OUTCOME Investigators (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. 373(22):2117-28. doi: 10.1056/NEJMoa1504720.
- [4] Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, *et al*. (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. *The Lancet Diabetes & Endocrinology*. doi:10.1016/s2213-8587(19)30256-6
- [5] Perkovic V, Mardine MJ, Neal B, *et al*. CREDENCE Trial Investigators (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med* 380: 2295-2306.
- [6] Bernstein RK (1997) *Dr. Bernstein's Diabetes Solution*. Little, Brown and company, New York.
- [7] Shai I, Schwarzfuchs D, Henkin Y, *et al*. (2008) Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet. *N Engl J Med*. 359: 229-241.
- [8] Tay J, Thompson CH, Luscombe-Marsh ND, *et al*. (2018) Effects of an energy-restricted low carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: A 2-year randomized clinical trial. *Diabetes Obes Metab*. 20:858–871. <https://doi.org/10.1111/dom.13164>
- [9] Ebe K, Ebe Y, Yokota S, Matsumoto T, Hashimoto M, Sakai Y, *et al*. (2004) Low Carbohydrate diet (LCD) treated for three cases as diabetic diet therapy. *Kyoto Medical Association Journal* 51: 125-129.
- [10] Bando H, Ebe K, Muneta T, Bando M, Yonei Y (2017) Effect of low carbohydrate diet on type 2 diabetic patients and usefulness of M-value. *Diabetes Res Open J*. 2017; 3(1): 9-16. doi: 10.17140/DROJ-3-130.
- [11] Ebe K, Bando H, Yamamoto K, Bando M, Yonei Y (2018) Daily carbohydrate intake correlates with HbA1c in low carbohydrate diet (LCD). *J Diabetol* 1(1): 4-9.
- [12] Bando H (2018) Clinically Beneficial Application of Flash Glucose Monitoring (FGM). *Biomed J Sci & Tech Res* 11(3)-2018.BJSTR. MS.ID.002095. DOI: 10.26717/ BJSTR.2018.11.002095.
- [13] Bode BW, Iotova V, Kovarenko M, Laffel LM, Rao P V, Deenadayalan S, Danne T (2019) Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial. *Diabetes Care*, dc190009. doi:10.2337/dc19-0009
- [14] Slattery D, Choudhary P (2017) Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes. *Diabetes Technol Ther* 19(S2):S55-S61. doi: 10.1089/dia.2017.0051.
- [15] Carlson A, Kanapka L, Miller K, Ahmann A, Chaytor N, Fox S, *et al*. (2019) OR22-2 Exposure to Hypoglycemia in Older Adults with Type 1 Diabetes: Baseline Characteristics Using Continuous Glucose Monitoring Data. *J Endocr Soc* 3 (s1). doi.org/10.1210/js.2019-OR22-2.
- [16] Messer LH, Cook PF, Tanenbaum ML, Hanes S, Driscoll KA, Hood KK, *et al*. (2019) CGM Benefits and Burdens: Two Brief Measures of Continuous Glucose Monitoring. *J Diab Sci Tech*. 2019-Mar.

doi.org/10.1177/1932296819832909.

- [17] Taylor PJ, Thompson CH, Luscombe-Marsh ND, Wycherley TP, Wittert G (2019) Efficacy of Real-Time Continuous Glucose Monitoring to Improve Effects of a Prescriptive Lifestyle Intervention in Type 2 Diabetes: A Pilot Study. *Diabetes Ther*: 10: 509. <https://doi.org/10.1007/s13300-019-0572-z>
- [18] Abbott Diabetes Care. <https://www.myfreestyle.com/freestyle-libre-pro-cgm-system>
- [19] Edge J, Acerini C, Campbell F, Hamilton-Shield J, Moudiotis C, Rahman S, *et al.* (2017) An alternative sensor-based method for glucose monitoring in children and young people with diabetes. *Arch Dis Child* 102(6):543-549. doi: 10.1136/archdischild-2016-311530.
- [20] Klonoff D, Bernhardt P, Ginsberg GH, *et al* (2008) A performance metrics for continuous interstitial glucose monitoring; approved guideline. Ed by Institute CalS, USA, CLSI, p1-57.
- [21] Vigersky RA: The benefits, limitations, and cost-effectiveness of advanced technologies in the management of patients with diabetes mellitus. *J Diabetes Sci Technol* 2015;9:320–330.
- [22] Rodbard D: Continuous glucose monitoring: a review of successes, challenges, and opportunities. *Diabetes Technol Ther* 2016;18 Suppl 2:S23–S213.
- [23] Peters AL, Ahmann AJ, Battelino T, *et al.*: Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2016;101:3922–3937.
- [24] Ajjan RA (2017) How Can We Realize the Clinical Benefits of Continuous Glucose Monitoring? *Diabetes Technol Therap* 19: suppl 27-36.
- [25] Kropff J, Choudhary P, Neupane S, *et al.*: Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. *Diabetes Care* 2017;40:63–68.
- [26] Pettus J, Price DA, Edelman SV (2015) How patients with type 1 diabetes translate continuous glucose monitoring data into diabetes management decisions. *Endocr Pract*. 21:613-620.
- [27] New JP, Ajjan R, Pfeiffer AF, Freckmann G (2015) Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS). *Diabet Med* 32:609-617.
- [28] Chamberlain JJ, Dopita D, Gilgen E, Neuman A (2015) Impact of frequent and persistent use of continuous glucose monitoring (CGM) on hypoglycemia fear, frequency of emergency medical treatment, and SMBG frequency after one year. *J Diabetes Sci Technol*. 2015;10(2):383-388.
- [29] Maiorino M, Petrizzo M, Bellastella G, *et al.*, Continuous glucose monitoring for patients with type 1 diabetes on multiple daily injections of insulin: pros and cons. *Endocrine* (2017). doi:10.1007/s12020-017-1328-z
- [30] Parkin CG, Graham C, Smolskis J (2017) Continuous Glucose Monitoring Use in Type 1 Diabetes: Longitudinal Analysis Demonstrates Meaningful Improvements in HbA1c and Reductions in Health Care Utilization. *Journal of Diabetes Science and Technology*. 11(3) 522–528
- [31] Giulio F, Valeria F, Clara B (2017) Comment on “The pros and cons of continuous glucose monitoring for patients with type 1 diabetes on multiple daily injections of insulin.” *Endocrine* 2017. DOI 10.1007/s12020-017-1358-6
- [32] Fokkert MJ, van Dijk PR, Edens MA, Abbes S, de Jong D, Slingerland RJ, *et al.* (2017) Performance of the FreeStyle Libre Flash glucose monitoring system in patients with type 1 and 2 diabetes mellitus. *BMJ Open Diabetes Res Care* 17;5(1):e000320. doi: 10.1136/bmjdr-2016-000320. eCollection 2017.
- [33] Ólafsdóttir AF, Attvall S, Sandgren U, Dahlqvist S, Pivodic A, Skrtic S, *et al.* (2017) A Clinical Trial of the Accuracy and Treatment Experience of the Flash Glucose Monitor FreeStyle Libre in Adults with Type 1 Diabetes. *Diabetes Technol Ther*. 19(3):164-172. doi: 10.1089/dia.2016.0392.
- [34] Schierenbeck F, Franco-Cereceda A, Liska J (2017) Accuracy of 2 Different Continuous Glucose Monitoring Systems in Patients Undergoing Cardiac Surgery. *J Diabetes Sci Technol*. 2017 Jan;11(1):108-116. doi: 10.1177/1932296816651632.
- [35] Kebede MM, Schuett C, Pschke CR (2019). The Role of Continuous Glucose Monitoring, Diabetes Smartphone Applications, and Self-Care Behavior in Glycemic Control: Results of a Multi-National Online Survey. *J Clin Med* 8: 109; doi:10.3390/jcm8010109